nach oben

Clinical and Experimental Nephrology

Erschienen in:

01.04.2014 | Preface

The kidney and lipids: preface

verfasst von: Bertram Kasiske, Takao Saito

Erschienen in: Clinical and Experimental Nephrology | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Excerpt

From June 5 through June 7, 2013, there was a World Congress of Nephrology 2013 Satellite Symposium on the Kidney and Lipids in Fukuoka, Japan. This meeting was held in conjunction with The 25th Annual Meeting of Japanese Society of Kidney and Lipids. There were 158 participants, all with an interest in the role of lipid abnormalities in chronic kidney disease (CKD). …

Nur mit Berechtigung zugänglich

Virchow R. A more precise account of fatty metamorphosis. In: Chance F, editor. Cellular pathology. 2nd ed. Birmingham: Gryphon Editions; 1860. p. 342–66.

Munk F. Die Nephrosen. Die Lipoidnephrose. Medsche Klin. 1916;12:1047–76.

Kimmelstiel P, Wilson C. Intercapillary lesions in the glomerulus of the kidney. Am J Pathol. 1936;12:83–98.PubMedCentralPubMed

Moorhead JF, Chan MK, El Nahas M, Varghese Z. Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet. 1982;2:1309–11.PubMedCrossRef

Keane WF, Yukawa S, Mune M. Lipids and renal disease. Kidney Int Suppl. 1999;56(S71):S1–259.CrossRef

Strom EH, Sund S, Reier-Nilsen M, Dorje C, Leren TP. Lecithin: cholesterol acyltransferase (LCAT) deficiency: renal lesions with early graft recurrence. Ultrastruct Pathol. 2011;35:139–45.PubMedCrossRef

Takahashi S, Hiromura K, Tsukida M, Ohishi Y, Hamatani H, Sakurai N, et al. Nephrotic syndrome caused by immune-mediated acquired LCAT deficiency. J Am Soc Nephrol. 2013;24:1305–12.PubMedCrossRef

Saito T, Matsunaga A, Oikawa S. Impact of lipoprotein glomerulopathy on the relationship between lipids and renal diseases. Am J Kidney Dis. 2006;47:199–211.PubMedCrossRef

Ishigaki Y, Oikawa S, Suzuki T, Usui S, Magoori K, Kim DH, et al. Virus-mediated transduction of apolipoprotein E (ApoE)-Sendai develops lipoprotein glomerulopathy in ApoE-deficient mice. J Biol Chem. 2000;275:31269–73.PubMedCrossRef

10.

Mooyaart AL, Valk EJ, Van Es LA, Bruijn JA, de Heer E, Freedman BI, et al. Genetic associations in diabetic nephropathy: a meta-analysis. Diabetologia. 2011;54(3):544–53.PubMedCentralPubMedCrossRef

11.

Genovese G, Friedman DJ, Ross MD, Lecordier L, Uzureau P, Freedman BI, et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science. 2010;329(5993):841–5.PubMedCentralPubMedCrossRef

12.

Friedman DJ, Kozlitina J, Genovese G, Jog P, Pollak MR. Population-based risk assessment of APOL1 on renal disease. J Am Soc Nephrol. 2011;22:2098–105.PubMedCentralPubMedCrossRef

13.

Freedman BI, Langefeld CD, Murea M, Ma L, Otvos JD, Turner J, et al. Apolipoprotein L1 nephropathy risk variants associate with HDL subfraction concentration in African Americans. Nephrol Dial Transpl. 2011;26:3805–10.CrossRef

14.

Muso E, Yashiro M, Matsushima M, Yoshida H, Sawanishi K, Sasayama S. Does LDL-apheresis in steroid-resistant nephrotic syndrome affect prognosis? Nephrol Dial Transpl. 1994;9:257–64.

15.

Muso E, Mune M, Yorioka N, Nishizawa Y, Hirano T, Hattori M, et al. Beneficial effect of low-density lipoprotein apheresis (LDL-A) on refractory nephrotic syndrome (NS) due to focal glomerulosclerosis (FGS). Clin Nephrol. 2007;67:341–4.PubMedCrossRef

16.

Holdaas H, Fellstrom B, Jardine AG, Holme I, Nyberg G, Fauchald P, et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet. 2003;361(9374):2024–31.PubMedCrossRef

17.

Holdaas H, Fellstrom B, Cole E, Nyberg G, Olsson AG, Pedersen TR, et al. Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study. Am J Transpl. 2005;5:2929–36.CrossRef

18.

Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353:238–48.PubMedCrossRef

19.

Fellström BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360:1395–407.PubMedCrossRef

20.

Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377(9784):2181–92.PubMedCentralPubMedCrossRef

21.

Upadhyay A, Earley A, Lamont JL, Haynes S, Wanner C, Balk EM. Lipid-lowering therapy in persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med. 2012;157:251–62.PubMedCrossRef

22.

Palmer SC, Craig JC, Navaneethan SD, Tonelli M, Pellegrini F, Strippoli GF. Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med. 2012;157:263–75.PubMedCentralPubMedCrossRef

23.

KDIGO. Clinical practice guideline for lipid management in chronic kidney disease. Kidney Int Suppl. 2013;3(3):1–80.

Titel: The kidney and lipids: preface
verfasst von: Bertram Kasiske
Takao Saito
Publikationsdatum: 01.04.2014
Verlag: Springer Japan
Erschienen in: Clinical and Experimental Nephrology / Ausgabe 2/2014
Print ISSN: 1342-1751
Elektronische ISSN: 1437-7799
DOI: https://doi.org/10.1007/s10157-014-0954-5

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

19.04.2024 | Vorhofflimmern | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

The kidney and lipids: preface

Excerpt

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2014

Serum lipids and prevention of atherosclerotic cardiovascular events in hemodialysis patients

Role of dyslipidemia in impairment of energy metabolism, oxidative stress, inflammation and cardiovascular disease in chronic kidney disease

Genetic associations in diabetic nephropathy

Do statins play a role in renoprotection?

World Congress of Nephrology (WCN) 2013 Satellite Symposium “Kidney and Lipids”, June 5–7, 2013, Fukuoka, Japan

Characteristics and 3-year mortality and infection rates among incident hemodialysis patients with a permanent catheter undergoing a first vascular access conversion

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Innere Medizin